Trial Profile

A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talimogene laherparepvec (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pegfilgrastim
Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 May 2025 Planned End Date changed from 31 Mar 2025 to 1 Feb 2026.
24 Jan 2025 Planned End Date changed from 31 Dec 2024 to 31 Mar 2025.
20 Dec 2024 Planned End Date changed from 31 Oct 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com